# A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

> **NCT03584009** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 103 (actual)

## Conditions studied

- Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT03584009
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-06
- **Primary completion:** 2020-08-05
- **Final completion:** 2021-05-06
- **Target enrollment:** 103 (ACTUAL)
- **Why stopped:** Sponsor's decision, no safety concerns.
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03584009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03584009, "A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03584009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*